Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Misetionamide - Persevere Therapeutics

Next Previous
Drug Profile

Misetionamide - Persevere Therapeutics

Alternative Names: GP-2250; substance 2250; Taurultam analogue

Latest Information Update: 12 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Geistlich; Panavance Therapeutics
  • Developer Geistlich; Panavance Therapeutics; Ruhr-University Bochum
  • Class Alkanesulfonic acids; Antibacterials; Antineoplastics; Small molecules; Thiadiazines
  • Mechanism of Action Apoptosis stimulants; Glyceraldehyde 3 phosphate dehydrogenase inhibitors; Hypoxia-inducible factor 1 alpha inhibitors; Ketoglutarate dehydrogenase complex inhibitors; Lipopolysaccharide inhibitors; NF-kappa B kinase inhibitors; Proto-oncogene protein c-myc inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Pancreatic cancer
  • Preclinical Breast cancer; Cancer; Colorectal cancer; Malignant melanoma; Mesothelioma; Neuroendocrine tumours; Ovarian cancer; Squamous cell cancer

Most Recent Events

  • 03 Mar 2026 Persevere Therapeutics acquires misetionamide from Geistlich Pharma and Panavance Therapeutics
  • 03 Mar 2026 Persevere Therapeutics plans a phase Ib/IIa trial for Ovaian cancer
  • 13 Jun 2025 Efficacy and adverse events data from a phase I trial in Cancer released by Panavance Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top